Novartis AG (NOVN) Given a CHF 87 Price Target at Kepler Capital Markets
Novartis AG (VTX:NOVN) has been given a CHF 87 price target by investment analysts at Kepler Capital Markets in a research report issued on Monday. The brokerage currently has a “buy” rating on the stock.
NOVN has been the topic of several other reports. Deutsche Bank AG set a CHF 81 price objective on Novartis AG and gave the company a “neutral” rating in a research note on Wednesday, July 19th. Morgan Stanley set a CHF 75 price objective on Novartis AG and gave the company a “sell” rating in a research note on Monday, May 29th. UBS AG set a CHF 76 price objective on Novartis AG and gave the company a “neutral” rating in a research note on Tuesday, July 18th. Sanford C. Bernstein set a CHF 94 price objective on Novartis AG and gave the company a “buy” rating in a research note on Tuesday, July 18th. Finally, J P Morgan Chase & Co set a CHF 70 price objective on Novartis AG and gave the company a “neutral” rating in a research note on Saturday, May 20th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of CHF 84.67.
Novartis AG (NOVN) traded down 1.00% during midday trading on Monday, hitting CHK 79.40. 3,494,786 shares of the stock were exchanged. Novartis AG has a one year low of CHK 67.40 and a one year high of CHK 84.35. The firm has a market capitalization of CHK 186.03 billion and a price-to-earnings ratio of 28.99. The company has a 50 day moving average price of CHK 80.87 and a 200 day moving average price of CHK 78.05.
TRADEMARK VIOLATION NOTICE: “Novartis AG (NOVN) Given a CHF 87 Price Target at Kepler Capital Markets” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/28/novartis-ag-novn-given-a-chf-87-price-target-at-kepler-capital-markets.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.